Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Dec 14, 2020
Xenetic Biosciences, Inc. Announces $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Dec 10, 2020
Xenetic Biosciences, Inc. Announces Positive Data from Partner’s Pivotal Phase 3 Clinical Trial Utilizing PolyXen(R) Platform Technology Dec 9, 2020
Xenetic Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update Nov 13, 2020
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Sep 9, 2020
Xenetic Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update Aug 13, 2020
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Two Key Appointments Jul 30, 2020
Xenetic Biosciences, Inc. Provides Development Update for Its Personalized CAR T Platform Technology, XCART(TM) Jul 1, 2020
Xenetic Biosciences, Inc. Announces Collaboration with Pharmsynthez and Multiple Academic Institutions in Russia and Belarus to Advance Development of XCART(TM) Platform Jun 16, 2020
